Comparable Efficacy of Low- Versus High-Dose Induction Corticosteroid Treatment in Autoimmune Pancreatitis

Jorie Buijs, MJ Heerde, EAJ Rauws, LJMD Wenniger, Bettina Hansen, Katharina Biermann, Joanne Verheij, FP Vleggaar, MA Brink, UHW Beuers, Ernst Kuipers, Marco Bruno, Henk van Buuren

Research output: Contribution to journalArticleAcademicpeer-review

37 Citations (Scopus)

Abstract

Objective The objective of this study was to compare efficacy of high versus low doses of prednisone for induction of remission in autoimmune pancreatitis (AIP). Methods This is a retrospective, multicenter study including patients diagnosed with AIP between May 1992 and August 2011. Clinical, laboratory and imaging findings were assessed before treatment and at 1, 3, and 6 months after starting treatment. Results A total of 65 patients (57 males; median age, 63 years) were treated with an initial low dose (10-20 mg/d, n = 14), a medium dose (30 mg/d, n = 15), or a high dose (40-60 mg/d, n = 36) of prednisone. There were no significant differences in baseline characteristics between the treatment groups including age, presenting symptoms and laboratory results. During a follow-up period of 6 months, in nearly all patients, symptoms (jaundice, weight loss) resolved completely. After 6 months, treatment response with respect to symptomatic, radiological, and laboratory improvement was comparable for the different dosage groups. Conclusions Response to therapy was comparable for AIP patients treated with doses of prednisone in the range of 10 to 60 mg/d. A prospective trial should be conducted to confirm efficacy of lower-dose prednisone treatment.
Original languageUndefined/Unknown
Pages (from-to)261-267
Number of pages7
JournalPancreas
Volume43
Issue number2
DOIs
Publication statusPublished - 2014

Research programs

  • EMC MM-03-24-01
  • EMC MM-04-20-01
  • EMC MM-04-20-02-A

Cite this